{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:17:48Z","timestamp":1778944668442,"version":"3.51.4"},"reference-count":71,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To assess the current literature for blinatumomab in the treatment of adult and pediatric B-cell acute lymphoblastic leukemia (ALL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>We conducted a PubMed (inception to December 11, 2020) and ClinicalTrials.gov systematic literature search using the following terms: blinatumomab, Blincyto, lymphoblastic leukemia, and bispecific T-cell engager.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>All relevant published articles, package inserts, and meeting abstracts evaluating the use of blinatumomab in ALL were considered for inclusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>Blinatumomab, a first-in-class bispecific T-cell engager monoclonal antibody, facilitates cytotoxic T-cell activation and subsequent eradication of CD19-positive B cells. The confirmatory phase III TOWER trial demonstrated superior overall survival (OS) with blinatumomab compared with standard chemotherapy (7.7 months vs 4.0 months) in relapsed and refractory (R\/R) B-cell ALL. In the phase II BLAST trial, blinatumomab achieved a complete measurable residual disease (MRD) response in 78% of evaluable patients, with a median OS of 36.5 months. Potentially life-threatening cytokine release syndrome and neurotoxicity occurred in approximately 15% and 65% of patients, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice:<\/jats:title>\n                    <jats:p>Following initial Food and Drug Administration approval in 2014, blinatumomab gained expanded approval in pediatric patients and in Philadelphia chromosome-positive R\/R ALL. In 2018, blinatumomab became the first and only drug approved for the treatment of persistent MRD in any hematologic malignancy. Emerging data demonstrate promising efficacy with blinatumomab in specific ALL settings, including frontline therapy, as a bridge to transplantation, and in \u201cchemotherapy-free\u201d combination regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Blinatumomab provides a paradigm-shifting treatment option; however, many questions surrounding optimal patient selection, sequencing, and cost-effectiveness remain.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1060028020988411","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T21:55:03Z","timestamp":1610661303000},"page":"1236-1253","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":16,"title":["A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions"],"prefix":"10.1177","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7032-0398","authenticated-orcid":false,"given":"Zachery","family":"Halford","sequence":"first","affiliation":[{"name":"Union University College of Pharmacy, Jackson, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7738-3028","authenticated-orcid":false,"given":"Carli","family":"Coalter","sequence":"additional","affiliation":[{"name":"Union University College of Pharmacy, Jackson, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1935-4856","authenticated-orcid":false,"given":"Vanessa","family":"Gresham","sequence":"additional","affiliation":[{"name":"Jackson-Madison County General Hospital, Jackson, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1782-241X","authenticated-orcid":false,"given":"Tabitha","family":"Brown","sequence":"additional","affiliation":[{"name":"Erlanger Health System\/Children\u2019s Hospital at Erlanger, Chattanooga, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,1,13]]},"reference":[{"key":"bibr1-1060028020988411","unstructured":"National Cancer Institute. Cancer stat facts: leukemia\u2014acute lymphocytic leukemia (ALL). Accessed September 22, 2020. https:\/\/seer.cancer.gov\/statfacts\/html\/alyl.html"},{"key":"bibr2-1060028020988411","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6636a3"},{"key":"bibr3-1060028020988411","doi-asserted-by":"publisher","DOI":"10.4065\/80.11.1517"},{"key":"bibr4-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01086"},{"key":"bibr5-1060028020988411","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.131680"},{"key":"bibr6-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-749507"},{"key":"bibr7-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2008.09.001"},{"key":"bibr8-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.13"},{"key":"bibr9-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0580"},{"key":"bibr10-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"bibr11-1060028020988411","first-page":"670","volume":"9","author":"Williams S","year":"2018","journal-title":"J Adv Pract Oncol"},{"key":"bibr12-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz017"},{"key":"bibr13-1060028020988411","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00135"},{"key":"bibr14-1060028020988411","first-page":"273","volume":"5","author":"Ehrlich P","year":"1909","journal-title":"Ned Tijdschr Geneeskd"},{"key":"bibr15-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4402274"},{"key":"bibr16-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-4094"},{"key":"bibr17-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71170-2"},{"key":"bibr18-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2012.07.013"},{"key":"bibr19-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-018-0760-1"},{"key":"bibr20-1060028020988411","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.4.2.19000"},{"key":"bibr21-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.41"},{"key":"bibr22-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26594"},{"key":"bibr23-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718395"},{"key":"bibr24-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-015-0213-6"},{"key":"bibr25-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2017.1396890"},{"key":"bibr26-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1020"},{"key":"bibr27-1060028020988411","unstructured":"Janeway CAJr, Travers P, Walport M, et al. The structure of a typical antibody molecule. In: Immunobiology: The Immune System in Health and Disease. 5th ed. Garland Science; 2001. Accessed January 4, 2021. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK27144\/"},{"key":"bibr28-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0405-4"},{"key":"bibr29-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2008.06.002"},{"key":"bibr30-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1126\/science.1158545"},{"key":"bibr31-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.1586"},{"key":"bibr32-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.3247"},{"key":"bibr33-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-649111"},{"key":"bibr34-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0447-x"},{"key":"bibr35-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0612"},{"key":"bibr36-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3301"},{"key":"bibr37-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.7712"},{"key":"bibr38-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0117-0"},{"key":"bibr39-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00342-x"},{"key":"bibr40-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29646"},{"key":"bibr41-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.3531"},{"key":"bibr42-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30558"},{"key":"bibr43-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0179"},{"key":"bibr44-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2016272"},{"key":"bibr45-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-627935"},{"key":"bibr46-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.7270"},{"key":"bibr47-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-441030"},{"key":"bibr48-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-798322"},{"key":"bibr49-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1780583"},{"key":"bibr50-1060028020988411","unstructured":"Blincyto\u00ae. Package insert. Amgen; 2020."},{"key":"bibr51-1060028020988411","volume-title":"Common Terminology Criteria for Adverse Events","author":"US Department of Health and Human Services","year":"2017"},{"key":"bibr52-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"bibr53-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"bibr54-1060028020988411","unstructured":"Actemra\u00ae. Package insert. Genentech; 2017."},{"key":"bibr55-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-804658"},{"key":"bibr56-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"bibr57-1060028020988411","unstructured":"Nelson R. New leukemia drug tops the charts with a $178,000 price tag. Published December 18, 2014. Accessed September 25, 2020. https:\/\/www.medscape.com\/viewarticle\/836879"},{"key":"bibr58-1060028020988411","unstructured":"IBM Micromedex\u00ae REDBOOK\u00ae\n                      (electronic version). Greenwood Village, CO: Truven Health Analytics. Accessed October 15, 2020. https:\/\/www.micromedexsolutions.com\/micromedex2\/librarian\/CS\/21EA02\/ND_PR\/evidencexpert\/ND_P\/evidencexpert\/DUPLICATIONSHIELDSYNC\/CD3332\/ND_PG\/evidencexpert\/ND_B\/evidencexpert\/ND_AppProduct\/evidencexpert\/ND_T\/evidencexpert\/PFActionId\/redbook.ShowProductSearchResults?SearchTerm=BLINCYTO&searchType=redbookProductName&searchTermId=43223&searchContent=REDBOOK&searchFilterAD=filterADActive&searchFilterRepackager=filterExcludeRepackager&searchPattern=%5Eblincyto"},{"key":"bibr59-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2017.1344127"},{"key":"bibr60-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1162\/rest.90.3.573"},{"key":"bibr61-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.12195"},{"key":"bibr62-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1405158"},{"key":"bibr63-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1177\/2040620714565963"},{"key":"bibr64-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb02559.x"},{"key":"bibr65-1060028020988411","unstructured":"National Comprehensive Cancer Network. Acute lymphoblastic leukemia (version 2.2020). Accessed October 30, 2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/all.pdf"},{"key":"bibr66-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"bibr67-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2016.09.003"},{"key":"bibr68-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509277"},{"key":"bibr69-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129657"},{"key":"bibr70-1060028020988411","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32909"},{"key":"bibr71-1060028020988411","first-page":"2815","volume":"130","author":"Lorenczeski G","year":"2017","journal-title":"Blood"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020988411","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028020988411","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020988411","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:16:06Z","timestamp":1777374966000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028020988411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,13]]},"references-count":71,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1177\/1060028020988411"],"URL":"https:\/\/doi.org\/10.1177\/1060028020988411","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,13]]}}}